Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ally Bridge Leads $65 Million Round in Pulmonx, a COPD Device Company

publication date: May 10, 2019

Ally Bridge Group of Hong Kong led an over-subscribed $65 million financing of Pulmonx, a Bay Area pulmonary device maker. Pulmonx develops technologies that improve the lives of patients suffering from COPD. Its major product, Zephyr Valve, is the first minimally-invasive device approved by the US FDA to treat patients with severe emphysema, a life-threatening form of COPD. Since 2007, more than 15,000 patients have been treated with the Zephyr Valve worldwide. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here